Navigation Links
AMRESCO’s New VisiGlo™ Prime and VisiGlo™ Select HRP Chemiluminescent Substrate Kits Offer Long-lasting, High Sensitivity Detection

Solon, Ohio (PRWEB) March 31, 2013

Chemiluminescent substrates are standard reagents for the detection of horseradish peroxidase (HRP) in Western blotting. Not all substrates perform equally, however. Critical characteristics to consider for chemiluminescent substrate selection are the sensitivity required to detect a target of interest, the stability of the signal generated and the ability to quantify the signal. AMRESCO’s VisiGlo™ HRP Chemiluminescent Substrate Kit with picogram sensitivity is now one of three VisiGlo™ options available after the addition of VisiGlo™ Prime and VisiGlo™ Select HRP Chemiluminescent Substrate Kits to their repertoire. The different formulations, from low to high sensitivity, allow HRP detection across a broad range of Western blotting conditions.

AMRESCO's new VisiGlo™ Prime HRP Chemiluminescent Substrate Kit is ideal for accurate protein quantitation, with a linear dynamic range of signal versus protein concentration encompassing over three orders of magnitude. The substrate has attomolar sensitivity and can detect both low and high abundance protein on a single blot exposure without exhibiting substrate depletion, a phenomenon observed as inverse staining of highly concentrated protein. The chemiluminescent emission from VisiGlo™ Prime is highly stable, lasting hours after substrate incubation to allow time for optimizing exposures. VisiGlo™ Prime is recommended for use with CCD imagers or film.

VisiGlo™ Select HRP Chemiluminescent Substrate Kit combines a broad linear dynamic range and low femtogram sensitivity to enable quantitation of low-abundance targets that other substrates may not reveal. The sensitivity and high signal-to-noise ratio permit target detection with minimal consumption of valuable protein and antibody reagents and allow long exposure times without compromising image quality. The signal generated by VisiGlo™ Select incubation is stable for hours and may be captured by film, CCD and fluorescence-based imaging systems for maximum flexibility.

AMRESCO’s VisiGlo™ chemiluminescent substrates are designed to achieve maximum signal-to-noise ratios in various blotting conditions. VisiGlo™ is best suited for moderate to high abundance protein detection, while VisiGlo™ Select offers the most intense signal for use in blotting with low abundance targets. For sensitivity and accurate quantitation, VisiGlo™ Prime’s wide dynamic linear range is an ideal choice. The chemiluminescent signals of the three VisiGlo™ options are all compatible with CCD and film imaging. VisiGlo™ Select also works with fluorescent imaging systems.

For more information about the VisiGlo™ HRP, VisiGlo™ Prime and VisiGlo™ Select substrates or any other AMRESCO products, visit or call 1-800-448-4442.

AMRESCO is a manufacturer and supplier of high quality biochemicals and reagents for life sciences in applications including molecular biology, proteomics, histology and clinical research. The company is ISO certified to ensure customers receive the highest quality products.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PrimeraDx to Co-Develop Companion Diagnostics with Quest Diagnostics
2. Honble Prime Minister Dr. Manmohan Singh Inaugurates TERIs Delhi Sustainable Development Summit (DSDS) 2013 on Global Challenge of Resource-Efficient Growth and Development
3. Burns Engineering Announces Expanded Selection of Miniature Temperature Sensors
4. ExakTime’s GeoTrakker Selected for 2013 Most Innovative Product Award Program
5. Medical University of South Carolina Selects Elseviers Interdisciplinary Care Planning and Clinical Documentation Solution
6. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
7. Greenwood Genetic Center Selects Cartagenia BENCHlab NGS, CNV Solutions for Clinical Data Analysis
8. Greenphires ClinCard Technology Platform selected by Bavarian Nordic for Major Vaccine Trial
9. OPX Biotechnologies Selected as Innovation Pioneer at IHS CERAWeek
10. New York Genome Institute Selects Exemplar LIMS to Manage Next Gen Sequencing Labs
11. Ono Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry
Post Your Comments:
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... event of the year and one of the premier annual events for pharmaceutical ... ran from 8–11 November 2015, where ISPE hosted the largest number of attendees ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
Breaking Biology Technology:
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):